Cargando…
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
BACKGROUND: Palbociclib is indicated for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer (ABC). OBJECTIVE: Exposure-response analyses were conducted to evaluate efficacy in Asian versus non-Asian patients and in patients with versus without dose re...
Autores principales: | Zheng, Jenny, Yu, Yanke, Durairaj, Chandrasekar, Diéras, Véronique, Finn, Richard S., Wang, Diane D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810610/ https://www.ncbi.nlm.nih.gov/pubmed/33211314 http://dx.doi.org/10.1007/s11523-020-00771-5 |
Ejemplares similares
-
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer
por: Durairaj, Chandrasekar, et al.
Publicado: (2018) -
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
por: Zhu, Zhou, et al.
Publicado: (2022) -
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: Ismail, R.K., et al.
Publicado: (2021) -
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019) -
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)